Volume 20, Issue 2, Pages (February 2013)

Slides:



Advertisements
Similar presentations
Michael T. Jacobsen, Michael Fairhead, Per Fogelstrand, Mark Howarth 
Advertisements

Cheng-Ming Sun, Edith Deriaud, Claude Leclerc, Richard Lo-Man  Immunity 
Volume 24, Issue 8, Pages e5 (August 2017)
Volume 21, Issue 2, Pages (February 2014)
Volume 28, Issue 2, Pages (February 2008)
Volume 20, Issue 11, Pages (November 2013)
Volume 22, Issue 7, Pages (July 2015)
Volume 14, Issue 2, Pages (February 2007)
Grigory S. Filonov, Vladislav V. Verkhusha  Chemistry & Biology 
Volume 14, Issue 11, Pages (November 2007)
Volume 36, Issue 6, Pages (June 2012)
Volume 18, Issue 2, Pages (February 2003)
Volume 20, Issue 1, Pages (January 2013)
Volume 21, Issue 11, Pages (November 2014)
Volume 25, Issue 3, Pages (March 2017)
Volume 39, Issue 5, Pages (November 2013)
Marek W.J. Whitehead, Nikolay Khanzhin, Lubor Borsig, Thierry Hennet 
Volume 22, Issue 10, Pages (October 2015)
Volume 21, Issue 2, Pages (February 2014)
Matthew Levy, Andrew D. Ellington  Chemistry & Biology 
Volume 14, Issue 10, Pages (October 2007)
Raluca Ostafe, Radivoje Prodanovic, Jovana Nazor, Rainer Fischer 
Volume 14, Issue 1, Pages (January 2004)
Grigory S. Filonov, Vladislav V. Verkhusha  Chemistry & Biology 
Volume 14, Issue 10, Pages (October 2007)
Jennifer J Kohler, Carolyn R Bertozzi  Chemistry & Biology 
Volume 22, Issue 3, Pages (March 2015)
Volume 16, Issue 4, Pages (April 2009)
Volume 16, Issue 11, Pages (November 2009)
Volume 47, Issue 4, Pages e3 (October 2017)
S100A15, an Antimicrobial Protein of the Skin: Regulation by E
Volume 19, Issue 12, Pages (December 2012)
Alexander Falkenhagen, Sadhna Joshi  Molecular Therapy - Nucleic Acids 
Volume 22, Issue 6, Pages (June 2015)
Volume 19, Issue 7, Pages (July 2012)
Volume 22, Issue 11, Pages (November 2015)
Volume 19, Issue 8, Pages (August 2012)
Active Caspase-1 Is a Regulator of Unconventional Protein Secretion
Michael T. Jacobsen, Michael Fairhead, Per Fogelstrand, Mark Howarth 
Volume 16, Issue 4, Pages (April 2009)
Volume 25, Issue 5, Pages (November 2006)
Volume 15, Issue 1, Pages 5-11 (January 2008)
Granulin Is a Soluble Cofactor for Toll-like Receptor 9 Signaling
Volume 20, Issue 1, Pages (January 2013)
Volume 16, Issue 2, Pages (February 2009)
Kevin M. Marks, Michael Rosinov, Garry P. Nolan  Chemistry & Biology 
Volume 20, Issue 5, Pages (May 2013)
Volume 15, Issue 12, Pages (December 2008)
Volume 21, Issue 5, Pages (May 2014)
Volume 16, Issue 12, Pages (June 2006)
Inhibitor Mediated Protein Degradation
An Electrophoretic Mobility Shift Assay Identifies a Mechanistically Unique Inhibitor of Protein Sumoylation  Yeong Sang Kim, Katelyn Nagy, Samantha Keyser,
Volume 22, Issue 11, Pages (November 2015)
UA62784 Is a Cytotoxic Inhibitor of Microtubules, not CENP-E
Volume 18, Issue 4, Pages (April 2011)
Volume 42, Issue 4, Pages (April 2015)
Volume 29, Issue 3, Pages (March 2016)
Analyzing Fission Yeast Multidrug Resistance Mechanisms to Develop a Genetically Tractable Model System for Chemical Biology  Shigehiro A. Kawashima,
Volume 18, Issue 1, Pages (January 2011)
Cytotoxic T Lymphocyte Antigen-4 Accumulation in the Immunological Synapse Is Regulated by TCR Signal Strength  Jackson G. Egen, James P. Allison  Immunity 
Volume 12, Issue 9, Pages (September 2005)
Growth Factor-Dependent Trafficking of Cerebellar NMDA Receptors via Protein Kinase B/Akt Phosphorylation of NR2C  Bo-Shiun Chen, Katherine W. Roche 
Aaron T. Wright, Benjamin F. Cravatt  Chemistry & Biology 
Volume 68, Issue 3, Pages e5 (November 2017)
Volume 38, Issue 3, Pages (March 2013)
Volume 13, Issue 11, Pages (November 2006)
Volume 14, Issue 8, Pages (August 2007)
Volume 17, Issue 8, Pages (August 2010)
Volume 99, Issue 1, Pages e3 (July 2018)
Volume 22, Issue 1, Pages (January 2015)
Presentation transcript:

Volume 20, Issue 2, Pages 202-211 (February 2013) Directed Evolution of a Soluble Human IL-17A Receptor for the Inhibition of Psoriasis Plaque Formation in a Mouse Model  Marianna Zaretsky, Revital Etzyoni, Joel Kaye, Liora Sklair-Tavron, Amir Aharoni  Chemistry & Biology  Volume 20, Issue 2, Pages 202-211 (February 2013) DOI: 10.1016/j.chembiol.2012.11.012 Copyright © 2013 Elsevier Ltd Terms and Conditions

Chemistry & Biology 2013 20, 202-211DOI: (10. 1016/j. chembiol. 2012 Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 1 YSD of the Extracellular Domain of IL-17RA (A) IL-17RA is displayed as an Aga2 fusion protein on the surface of yeast. Expression is detected using fluorescent antibodies binding to the c-myc tag. Binding of IL-17RA to IL-17A is detected using biotinylated α-IL-17A antibodies and then fluorescently-labeled streptavidin. (B) FACS histogram analysis of cells displaying WT IL-17RA (red), the PCNA that was used as a positive control (green), and yeast cells containing no plasmid that was used as a negative control (black). (C and D) Enrichment of the IL-17RA back-to-consensus library using YSD for higher display level and binding to IL-17A. FACS histogram analysis of cells displaying the naive library (black) and the library following one round (blue) or two rounds (orange) of enrichment. Expression of IL-17RA mutants was examined following incubation with FITC-conjugated antibodies directed against the c-myc epitope (C). Binding to IL-17A was measured following incubation with IL-17A, biotinylated antibodies, and APC-labeled streptavidin (D). See also Figures S2 and S3 and Table S1. Chemistry & Biology 2013 20, 202-211DOI: (10.1016/j.chembiol.2012.11.012) Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 2 Thermal Inactivation of WT IL-17RA, V3, and V10 Mutants The IL-17RA variants were incubated at different temperatures for 30 min, and residual IL-17RA binding to IL-17A was monitored at room temperature using ELISA. The results were normalized relative to the variant binding following incubation at 50°C. The heat inactivation temperatures derived from the fits are 57.1 ± 0.6, 63.8 ± 1.2, and 63.9 ± 0.5 for the WT (triangle), V3 (filled circle), and V10 (empty circle), respectively. Each data point is the average of two independent experiments, see details in the Experimental Procedures section. See also Figures S5, S6, and S8 and Table S4. Chemistry & Biology 2013 20, 202-211DOI: (10.1016/j.chembiol.2012.11.012) Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 3 The V3 and V10 Variants Are More Potent in Inhibiting IL-17A-Induced Secretion of Gro-α in Human Fibroblasts than Is WT IL-17RA Cells were incubated for 24 hr with 10 ng/ml hIL-17A and different concentrations of soluble IL-17RA WT and mutant receptors. The undiluted cell supernatant was analyzed by ELISA for detection of Gro-α levels. The values presented here were calculated following subtraction of the basal Gro-α secretion signal (OD450 = 0.2). The data represent the average of three independent repeats of each experiment and the error bars represent the standard deviation from the average. See also Figures S5, S6, S8, and S9 and Table S4. Chemistry & Biology 2013 20, 202-211DOI: (10.1016/j.chembiol.2012.11.012) Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 4 The V3 and V10 Variants Inhibit IL-17A-Induced Secretion of Gro-α in Mice More Efficiently than Does WT IL-17RA Injection of IL-17A (1.5 mg/kg) into groups of mice (n = 5 in each group) leads to significant increases in Gro-α levels. Pre-incubation of IL-17A with antibody against IL-17A (2 mg/kg), WT IL-17RA, V3, or V10 leads to inhibition of Gro-α secretion. The antibody against IL-17A was used as a positive control for IL-17A-induced Gro-α secretion in vivo. We found that the inhibition of IL-17A-induced Gro-α secretion is significantly higher with the V3 or V10 than the inhibition obtained with WT. All IL-17RA variants were injected at a concentration of 14 mg/kg and Gro-α levels were analyzed in blood samples collected 2 hr after injection (see Experimental Procedures for detailed description). The data represent the average of five independent measurements (five mice in each group) and the error bars represent the standard deviation from the average. See also Figures S7 and S8. Chemistry & Biology 2013 20, 202-211DOI: (10.1016/j.chembiol.2012.11.012) Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 5 The Recovery of Psoriasis Lesions following Administration of V3 IL-17R Variant at Different Concentrations A dose response for V3 activity is observed between 3.5 and 7 mg/kg; attenuated activity at higher doses was observed. Doses were administered via subcutaneous injection twice a week for 4 weeks in the psoriasis model at concentrations of 3.5, 7, 14, and 28 mg/kg. The data represent the average of eight independent measurements (eight mice in each group) and the error bars represent the standard deviation from the average. See also Figure S7 and Table S5. Chemistry & Biology 2013 20, 202-211DOI: (10.1016/j.chembiol.2012.11.012) Copyright © 2013 Elsevier Ltd Terms and Conditions